Total Voting Rights and Block Listing Return

Oct 03, 2022
RNS Number : 5404B
MaxCyte, Inc.
03 October 2022
 

MaxCyte, Inc.

 

("MaxCyte" or the "Company")

 

TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN

 

 

Total Voting Rights

Date: 3 October 2022: MaxCyte (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, announces that pursuant to its block admission facility, it has recently issued 47,429 of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options. The new Common Stock will rank pari passu with the existing shares of common stock of the Company.

As of 30 September 2022, the total issued stock capital of the Company following the recent issue of the new Common Stock is 101,904,313 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

 

Block Listing Return

 

MaxCyte also makes the following notification pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies, regarding its existing block listings:

 

Name of applicant:

MaxCyte, Inc.

Name of scheme:

MaxCyte Long Term Incentive Plan

Period of return:

From:

1 March 2022

To:

30 September 2022

Balance of unallotted securities under scheme(s) from previous return:

12,177,084 ordinary shares of common stock at $0.01 each

Plus:  The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

647,481 ordinary shares of common stock at $0.01 each

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

11,529,603 ordinary shares of common stock at $0.01 each

 

Name of contact:

Ron Holtz, Chief Financial Officer

Telephone number of contact:

+1 301 944 1624

 

 


For further information, please contact:

 

MaxCyte Contacts:

US IR Adviser

Gilmartin Group

David Deuchler, CFA

 

 

 

 

+1 415-937-5400

ir@maxcyte.com

 



Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl / Freddy Crossley

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500



 

UK IR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh 

 

 

+44 (0)203 709 5700

maxcyte@consilium-comms.com

 


 

 

 






About MaxCyte

MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization. Over the past 20 years, we have developed and commercialized our proprietary Flow Electroporation®platform, which facilitates complex engineering of a wide variety of cells. Our ExPERT™ platform, which is based on our Flow Electroporation technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATx™, STx™ GTx™and VLx™; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRUPGRWUUPPURW